Skip to main content

Advertisement

SpringerLink
Log in

Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

HAb18G is a recently identified hepatoma-associated antigen and its association with tumor growth, invasion, and angiogenesis has been studied in a variety of tumors. However, its role in the tumor progression of breast cancer has not been explored. HAb18G expression was examined by immunohistochemistry in pathological sections of 1,637 breast tissue samples and by in situ hybridization in 41 cases of invasive breast carcinomas (BC). While not detected in any cases of tumor-like conditions or benign tumors of breast, and only rarely in normal tissue (4.4%), HAb18G expression was gradually up-regulated from atypical ductal hyperplasia (27.3%), to ductal carcinoma-in situ (59.8%), and to BC (61.4%) (P < 0.01). Its expression in BC was correlated positively with C-erbB-2 expression and histologic grade (P < 0.001), and negatively with the expression of estrogen and progesterone receptors (P < 0.001). Significant differences of expression were also identified among the subgroups of BC examined: in decreasing order from invasive micropapillary carcinoma, ductal carcinoma, lobular carcinoma, papillary carcinoma, medullary carcinoma, to mucinous adenocarcinoma (P = 0.001), corresponding to their known clinical aggressiveness. In an expanded group of 186 BC patients with proper follow up, our previous findings were confirmed: HAb18G expression was significantly associated with local recurrence, distant metastasis and tumor mortality (P < 0.01). We also demonstrated that up-regulated tumor expression of HAb18G was a significant predictor of reduced disease progression-free survival rate and a shorter overall survival, independent of systemic therapies. In conclusion, this study suggests that HAb18G expression is associated with BC progression and prognosis. Further evaluation of this new marker in breast cancer is indicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Chen ZN, Liu YF (1990) Monoclonal antibody HAb18 to human hepatoma. Monoclon Antib 8:11

    Google Scholar 

  2. Jiang JL, Zhou Q, Yu MK, Ho LS, Chen ZN, Chan HC (2001) The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells. J Biol Chem 276(50):46870–46877

    Article  CAS  PubMed  Google Scholar 

  3. Chen ZN, Shang P, Li Y, Qian AR, Zhu P, Xing JL, inventors (2002) NTD patent & trademark agency Ltd., Beijing office, assignee. HAb18G/CD147, its agonist and application. Chinese patent ZL01131735.3, 2001 Sep 28; PCT international patent WO02/094875, 27 May 2002

  4. Huang Y, Jiang J, Dou K, Chen Z (2005) HAb18G/CD147 enhances the secretion of matrix metalloproteinases (MMP) via cGMP/NO-sensitive capacitative calcium entry (CCE) and accordingly attenuates adhesion ability of fibroblasts. Eur J Cell Biol 84(1):59–73

    Article  CAS  PubMed  Google Scholar 

  5. Li Y, Shang P, Qian AR, Wang L, Yang Y, Chen ZN (2003) Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinoma cells in vitro. World J Gastroenterol 9(10):2174–2177

    CAS  PubMed  Google Scholar 

  6. Wang FQ, So J, Reierstad S, Fishman DA (2006) Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer 118(4):879–888

    Article  CAS  PubMed  Google Scholar 

  7. Jiang JL, Chan HC, Zhou Q, Yu MK, Yao XY, Lam SY, Zhu H, Ho LS, Leung KM, Chen ZN (2004) HAb18G/CD147-mediated calcium mobilization and hepatoma metastasis require both C-terminal and N-terminal domains. Cell Mol Life Sci 61(16):2083–2091

    Article  CAS  PubMed  Google Scholar 

  8. Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G, Xu J, Qian F, Chen Z (2006) CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 5(7):808–814

    Article  CAS  PubMed  Google Scholar 

  9. Zhang Q, Zhou J, Ku XM, Chen XG, Zhang L, Xu J, Chen GS, Li Q, Qian F, Tian R, Wen N, Chen ZN (2007) Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. Eur J Cancer Prev 16(3):196–202

    Article  PubMed  Google Scholar 

  10. Bao GQ, Li Y, Ma QJ, He XL, Xing JL, Yang XM, Chen ZN (2005) Isolating human antibody against human hepatocellular carcinoma by guided-selection. Cancer Biol Ther 4(12):1374–1380

    Article  CAS  PubMed  Google Scholar 

  11. Chen ZN, Mi L, Xu J et al (2006) Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 65(2):435–444

    CAS  PubMed  Google Scholar 

  12. Xu J, Shen ZY, Chen XG et al (2007) A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 45(2):269–276

    Article  CAS  PubMed  Google Scholar 

  13. Zheng HC, Takahashi H, Murai Y, Cui ZG, Nomoto K, Miwa S, Tsuneyama K, Takano Y (2006) Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer 95(10):1371–1378

    Article  CAS  PubMed  Google Scholar 

  14. Zhong WD, Han ZD, He HC, Bi XC, Dai QS, Zhu G, Ye YK, Liang YX, Qin WJ, Zhang Z, Zeng GH, Chen ZN (2008) CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 75(3–4):230–236

    Article  CAS  PubMed  Google Scholar 

  15. Sienel W, Polzer B, Elshawi K, Lindner M, Morresi-Hauf A, Vay C, Eder F, Passlick B, Klein CA (2008) Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Mod Pathol 21(9):1130–1138

    Article  CAS  PubMed  Google Scholar 

  16. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, Pantel K (2006) High incidence of EMMPRIN expression in human tumors. Int J Cancer 119(8):1800–1810

    Article  CAS  PubMed  Google Scholar 

  17. Li Y, Xu J, Chen L et al (2009) HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology 54(6):677–687

    Article  CAS  PubMed  Google Scholar 

  18. McShane LM et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067–9072

    Article  PubMed  Google Scholar 

  19. Zhao J, Liu H, Wang M, Gu L, Guo X, Gu F, Fu L (2009) Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Surg Oncol 100(2):89–94

    Article  PubMed  Google Scholar 

  20. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145

    Article  CAS  PubMed  Google Scholar 

  21. Guo H, Li R, Zucker S, Toole BP (2000) EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res 60(4):888–891

    CAS  PubMed  Google Scholar 

  22. Kanekura T, Chen X, Kanzaki T (2002) Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 99(4):520–528

    Article  CAS  PubMed  Google Scholar 

  23. Xu J, Xu HY, Zhang Q et al (2007) HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res 5(6):605–614

    Article  CAS  PubMed  Google Scholar 

  24. Tavassoli FA, Devilee P (2003) WHO classification of tumours. Pathology & genetics tumours of the breast and female genital organs. Lyon, IARC Press, pp 28–29

    Google Scholar 

Download references

Acknowledgments

Supported by grants from National “863” Program of China (2006AA02A249), National “973” Program of China (2009CB521700) and the Program for Changjiang Scholars and Innovative Research Team in University (IRT0743).

Author information

Authors and Affiliations

  1. Department of Breast Cancer Pathology and Research Laboratory, State Key Laboratory of Breast Cancer Research, Cancer Hospital of Tianjin Medical University, Tianjin, 300060, China

    Fangfang Liu, Lifang Cui, Ling Chen, Yahong Wang, Yu Fan, Ting Lei, Feng Gu, Ronggang Lang & Li Fu

  2. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi’an, 710032, China

    Yang Zhang & Zhinan Chen

  3. Department of Pathology and Laboratory Medicine, Temple University Hospital, Philadelphia, PA, USA

    Gordon A. Pringle & Xinmin Zhang

Authors
  1. Fangfang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lifang Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ling Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yahong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ting Lei
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Feng Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ronggang Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gordon A. Pringle
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Xinmin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Zhinan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Li Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zhinan Chen or Li Fu.

Additional information

Fangfang Liu, Lifang Cui, and Yang Zhang have contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 62 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, F., Cui, L., Zhang, Y. et al. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat 124, 677–688 (2010). https://doi.org/10.1007/s10549-010-0790-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-0790-6

Keywords

Search

Navigation